Erskine HE, Ferrari AJ, Nelson P, Polanczyk GV, Flaxman AD, Vos T, et al. Epidemiological modelling of attention-deficit/hyperactivity disorder and conduct disorder for the Global Burden of Disease Study 2010. J Child Psychol Psychiatry. 2013;54(12):1263–74.
Article
PubMed
Google Scholar
Sonuga-Barke EJ. Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry. 2005;57(11):1231–8.
Article
PubMed
Google Scholar
Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–65.
Article
PubMed
Google Scholar
Biederman J, Petty CR, Wilens TE, Fraire MG, Purcell CA, Mick E, et al. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry. 2008;165(1):107–15.
Article
PubMed
Google Scholar
Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011;31(3):328–41.
Article
PubMed Central
PubMed
Google Scholar
Riggs P, Levin F, Green AI, Vocci F. Comorbid psychiatric and substance abuse disorders: recent treatment research. Subst Abus. 2008;29(3):51–63.
Article
PubMed
Google Scholar
Riggs PD, Winhusen T, Davies RD, Leimberger JD, Mikulich-Gilbertson S, Klein C, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry. 2011;50(9):903–14.
Article
PubMed Central
PubMed
Google Scholar
Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011;20(1):17–37.
Article
PubMed Central
CAS
PubMed
Google Scholar
Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012;10:99.
Article
PubMed Central
PubMed
Google Scholar
Spiller HA, Hays HL, Aleguas Jr A. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs. 2013;27(7):531–43.
Article
CAS
PubMed
Google Scholar
Calipari ES, Ferris MJ, Salahpour A, Caron MG, Jones SR. Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. Nat Commun. 2013;4:2720.
Article
PubMed Central
PubMed
Google Scholar
Cleary L, Buber R, Docherty JR. Effects of amphetamine derivatives and cathinone on noradrenaline-evoked contractions of rat right ventricle. Eur J Pharmacol. 2002;451(3):303–8.
Article
CAS
PubMed
Google Scholar
Takeuchi A, Ahern TL, Henderson SO. Excited delirium. West J Emerg Med. 2011;12(1):77–83.
PubMed Central
PubMed
Google Scholar
Hysek CM, Simmler LD, Schillinger N, Meyer N, Schmid Y, Donzelli M, et al. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Int J Neuropsychopharmacol. 2014;17(3):371–81.
Article
CAS
PubMed
Google Scholar
Castellanos FX, Meyer E. Toward systems neuroscience of shared and distinct neural effects of medications used to treat attention-deficit/hyperactivity disorder. Biol Psychiatry. 2013;74(8):560–2.
Article
PubMed
Google Scholar
Birmes P, Coppin D, Schmitt L. Lauque D. Serotonin Syndrome. 2003;168(11):1439–42.
Google Scholar
Adler L, Wilens T, Zhang S, Durell T, Walker D, Schuh L, et al. Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence. Am J Addict. 2009;18(5):393–401.
Article
PubMed
Google Scholar
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 2009;339:b2700.
Article
Google Scholar
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (Clinical research ed). 2007;335(7624):806–8.
Article
Google Scholar
Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008;96(1–2):145–54.
Article
CAS
PubMed
Google Scholar
Wilens TE, Adler LA, Tanaka Y, Xiao F, D’Souza DN, Gutkin SW, et al. Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. Curr Med Res Opin. 2011;27(12):2309–20.
Article
PubMed Central
CAS
PubMed
Google Scholar
Green R, Moore D. ‘Kiddie drugs’ and controlled pleasure: recreational use of dexamphetamine in a social network of young Australians. Int J Drug Policy. 2009;20(5):402–8.
Article
PubMed
Google Scholar
Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs. 2013;27(1):15–30.
Article
CAS
PubMed
Google Scholar
Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, et al. Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults. PLoS One. 2013;8(1):e52991.
Article
PubMed Central
CAS
PubMed
Google Scholar
Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs. 2011;25(2):157–69.
Article
CAS
PubMed
Google Scholar
Perez de los Cobos J, Sinol N, Perez V, Trujols J. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction. Br J Clin Pharmacol. 2014;77(2):337–56.
Article
PubMed Central
CAS
PubMed
Google Scholar
Hill SL, El-Khayat RH, Sandilands EA, Thomas SH. Electrocardiographic effects of methylphenidate overdose. Clinical Toxicol (Philadelphia, Pa). 2010;48(4):342–6.
Article
CAS
Google Scholar
Barrett SP, Darredeau C, Pihl RO. Patterns of simultaneous polysubstance use in drug using university students. Human Psychopharmacol. 2006;21(4):255–63.
Article
Google Scholar
Barrett SP, Pihl RO. Oral methylphenidate-alcohol co-abuse. J Clin Psychopharmacol. 2002;22(6):633–4.
Article
CAS
PubMed
Google Scholar
Griffin 3rd WC, McGovern RW, Bell GH, Randall PK, Middaugh LD, Patrick KS. Interactive effects of methylphenidate and alcohol on discrimination, conditioned place preference and motor coordination in C57BL/6J mice. Psychopharmacology. 2013;225(3):613–25.
Article
PubMed Central
CAS
PubMed
Google Scholar
Griffin 3rd WC, Novak AJ, Middaugh LD, Patrick KS. The interactive effects of methylphenidate and ethanol on ethanol consumption and locomotor activity in mice. Pharmacol Biochem Behav. 2010;95(3):267–72.
Article
PubMed Central
CAS
PubMed
Google Scholar
Bruggisser M, Bodmer M, Liechti ME. Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets. Swiss Med Wkly. 2011;141:w13267.
PubMed
Google Scholar
McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf. 2009;32(11):1089–96.
Article
PubMed
Google Scholar
Koehm M, Kauert GF, Toennes SW. Influence of ethanol on the pharmacokinetics of methylphenidate’s metabolites ritalinic acid and ethylphenidate. Arzneimittelforschung. 2010;60(5):238–44.
CAS
PubMed
Google Scholar
Konstenius M, Jayaram-Lindstrom N, Beck O, Franck J. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend. 2010;108(1–2):130–3.
Article
CAS
PubMed
Google Scholar
Winhusen TM, Lewis DF, Riggs PD, Davies RD, Adler LA, Sonne S, et al. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(5):455–63.
Article
PubMed Central
CAS
PubMed
Google Scholar
Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 2010;33(10):821–42.
Article
CAS
PubMed
Google Scholar
Simons R, Martens M, Ramaekers J, Krul A, Klopping-Ketelaars I, Skopp G. Effects of dexamphetamine with and without alcohol on simulated driving. Psychopharmacology. 2012;222(3):391–9.
Article
PubMed Central
CAS
PubMed
Google Scholar
Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol. 2002;10(3):286–94.
Article
CAS
PubMed
Google Scholar
Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 2006;81(2):137–48.
Article
CAS
PubMed
Google Scholar
Baumann MH. Awash in a sea of ‘bath salts’: implications for biomedical research and public health. Addiction (Abingdon, England). 2014;109(10):1577–9.
Article
Google Scholar